| Prev Close | 59.67 |
| Open | 60.27 |
| Day Low/High | 60.08 / 60.54 |
| 52 Wk Low/High | 46.48 / 61.34 |
| Volume | 3.51M |
Astrazeneca PLC Sponsored ADR (AZN)
60.22
0.55
0.92
NASDAQ
| Exchange | NASDAQ |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
AstraZeneca Could Pause a While Before Challenging the Old Highs
Let's review the charts and indicators.
3 Strong Long-Term Buys for Uncertain Times
These pharmaceutical names have what it takes amid the current crisis and for the long run.
Amazon vs. Microsoft, Assessing the Virus, Sticking Up for Judy Shelton
Fed repo policy changes confirm that external issues are having only a small impact on U.S. economic performance.
Why AbbVie Looks Like a Bargain at These Levels
Nobody in AbbVie right now is in it for the past performance.
Genprex: The Bad and the Good of Capital Raises
For those who love a roll of the dice, GNPX may be worth a closer look.
3 Powerhouse Pharma Stock Favorites
These healthcare stalwarts look attractive for growth and income.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Jim Cramer: Demand Is Driving This Market to All-Time Highs
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
High Flyers and Low Flyers
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
Now at the Plate, Your Pinch Hitter, Bret Jensen
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
The New Small Biotechs Heating Up the Medical Cannabis Space
These companies are working to plant their flag in a new landscape.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Buy Struggling Progenics and Dynavax Here
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Novice Trade: EWU United Kingdom ETF
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Novice Trade: EWU ETF
This portfolio cannot be trusted to be diversified enough.
The Race to Cure Alzheimer's is On: These Are the Forerunners
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
I continue to see these names as bargains in the biotech and biopharma space.
Small Cap Biotech Bargains
Here are 2 small caps I continue to see as bargains in this space.
4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon
These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.
Watch Oncology Stocks Ahead of 2 Big Events
Data and industry conferences will likely be catalysts for shares in the space.
3 Potential Biotech Buyout Targets in the Second Quarter
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Possible Biotech Takeout Plays
A look at possible second-quarter M&A activity in the biotech sector.
